COTA’s Miruna Sasu: I left pharma to “turn the spigot on” in the real-world data industry

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Miruna Sasu spent more than 20 years as a digital health and innovation expert at life sciences companies—then came a realization:

“You can do all kinds of really cool technology things, but if you don’t have data, you can’t apply the technology; right?” Sasu said to The Cancer Letter. “Now that pharma companies can receive it and put it to good use, we want to turn the spigot on.”

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Matthew Bin Han Ong
Senior Editor
Table of Contents


Patients treated with first-line immunotherapy for advanced non-small cell lung cancer showed similar results in terms of survival, progression-free survival, and treatment duration, regardless of race or ethnicity, even with differences in income and insurance, a study published in the Journal of the National Comprehensive Cancer Network showed.
Matthew Bin Han Ong
Senior Editor